PharmAust Raises $1.873m via an Oversubscribed Placement
Filed with ASX · · 2 pages · English
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- New MPL analogues show greater anti-cancer activity
- New drugs patented for cancer in USA
- Epichem Update - progress on milestones and revenue targets
- Appendix 4C - Quarterly Report & Brief Company Update
- Monepantel reformulation project continues to progress
Later from Neurizon Therapeutics
- Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
- Epichem Awarded One Year Contract Extension from DNDi
- Monepantel reformulation successfully improves dose & taste
- Appendix 4C - Quarterly Report & Shareholders Update
- PharmAust receives $354k R&D Tax Incentive Refund
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics